Apogee therapeutics to host conference call to report interim results from the phase 1 healthy volunteer trial for apg990 and provide combination strategy update on march 3, 2025

San francisco and boston, feb. 28, 2025 (globe newswire) -- apogee therapeutics, inc., (nasdaq: apge), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (i&i) markets, including for the treatment of atopic dermatitis (ad), asthma, eosinophilic esophagitis (eoe), chronic obstructive pulmonary disease (copd) and other i&i indications, today announced it will report interim results from the phase 1 apg990 healthy volunteer trial on monday, march 3, 2025. following the announcement, the company will host a conference call and webcast at 8:30am et to discuss the results and plans for its combination approach for apg777 + apg990.
APG Ratings Summary
APG Quant Ranking